New Anti-Obesity Drug Approved by the FDA
Wegovy, a higher-dose variant of Novo Nordisk’s diabetes medicine semaglutide, has just been approved by the Food and Drug Administration (FDA) to solve long-term obesity and weight loss.
This new drug can help adults manage chronic weight issues or obese people suffering from weight-related illnesses, such as type 2 diabetes or high blood pressure. It’s the first chronic weight management drug to be approved by the FDA since 2014.
According to company-funded studies, patients who used Wegovy lost an average of 15% of their body weight or an estimated 34lbs. By comparison, in a group where the patients received placebo injections, the average weight loss was roughly 2.5% or slightly under 6lbs.
Many quality weight loss pills on the market effectively reduce body weight when combined with a balanced diet and sufficient exercise. However, Wegovy could be the best solution for struggling diabetics.
Wegovy acts as a synthetic form of a gastrointestinal hormone that, like appetite suppressants, can quell hunger levels in the body. Experts, however, recommend patients combine Wegovy use with a nutrient-dense diet and exercise.
Some common side effects are diarrhea, vomiting, and nausea. It’s also important to note that this new drug may put patients at risk of developing thyroid tumors. Therefore, people with a genetic predisposition to endocrine or thyroid tumors should avoid taking it.
Overall, this new anti-obesity injection shows promise. For those who are afraid of needles, Novo Nordisk is working on developing a pill variant of Wegovy.
Photo by NeONBRAND on Unsplash